FDA Approves Asmanex Twisthaler for Asthma
Asmanex Twisthaler contains mometasone furoate, a corticosteroid demonstrating potent antiinflammatory activity. Asmanex Twisthaler is indicated for the first-line maintenance treatment of asthma as preventive therapy in patients 12 years of age and older, and is also the only inhaled asthma controller therapy approved for once daily initiation and management of asthma in patients previously treated with bronchodilators alone or inhaled corticosteroids.Posted: March 2005
Related articles
- FDA Approves Asmanex Twisthaler (Mometasone Furoate InhalationPowder) for the Once Daily Maintenance Treatment of Asthma inChildren Ages 4-11 - February 4, 2008
Asmanex (mometasone furoate) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
